As an alternative to the conventional metered dose inhaler, dry powder inhalers (DPIs) offer proven benefits. These benefits, combined with a increased interest among medical and pharmaceutical researchers in utilizing the lung as the target of drug delivery, have driven a surge in the number of commercial opportunities for DPI products. What was once a delivery system only for respiratory drugs has now become a means for delivering medications for diabetes, pain management, influenza, and cystic fibrosis, as well as vaccines.
With so much potential revenue from DPI products, the search for viable technologies and intellectual property has intensified.
Porticos has experience in developing innovative technologies for containing and protecting powder doses, and in aerosolizing and deagglomerating drug powders.
Finding novel solutions to the challenges involved with delivering a small dose of powder is another example of our ability to help clients meet extreme engineering challenges.